已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Safety and Efficacy of Dupilumab in Adults and Adolescents With Asthma in the RAPID Registry

杜皮鲁玛 医学 哮喘 免疫学 单克隆 梅德林 重症监护医学 单克隆抗体 抗体 政治学 法学
作者
Njira Lucia Lugogo,Anju Tripathi Peters,Ole Hilberg,Allison Clare Ramsey,Xiong Chang-ming,Hashem Awad,R. Giannini
出处
期刊:American Journal of Respiratory and Critical Care Medicine [American Thoracic Society]
卷期号:211 (Supplement_1): A1370-A1370
标识
DOI:10.1164/ajrccm.2025.211.abstracts.a1370
摘要

RATIONALE: Dupilumab is a human monoclonal antibody that blocks interleukins 4 and 13, which are key and central drivers of type 2 inflammation in asthma. Dupilumab has proven efficacy and safety for the treatment of moderate-to-severe asthma in clinical trials, but real-world data are sparse. RAPID (NCT04287621) is a global, prospective registry characterizing patients with asthma who initiate dupilumab in real-world clinical practice. METHODS: RAPID enrolled 719 patients aged ≥12 years initiating dupilumab for asthma according to country-specific prescribing information. This analysis included the first 205 patients who completed 12 months in the study. Here, we report the unadjusted annualized severe exacerbation rate, asthma control assessed using the 6-item Asthma Control Questionnaire (ACQ-6; ranging from 0 = totally controlled, to 6 = severely uncontrolled), quality of life assessed by the Mini Asthma Quality of Life Questionnaire (Mini-AQLQ; ranging from 1 = worst quality of life, to 7 = best quality of life), and treatment-emergent adverse events (TEAEs) by Preferred Term. RESULTS: The mean (standard deviation [SD]) age of the 205 patients was 50.1 (17.4) years, and 134 (65.4%) were female. Patients experienced a mean (SD) of 1.9 (4.2) severe asthma exacerbations in the year before screening (Table). After 12 months in the study, the unadjusted severe asthma exacerbation rate was 0.14 (Table). Mean (SD) ACQ-6 score improved from 2.3 (1.2) at baseline to 1.1 (1.0) at Month 6 and 1.0 (1.1) at Month 12 (Table). Mini-AQLQ score improved from 4.1 (1.3) at baseline to 5.5 (1.3) at Month 6 and 5.5 (1.4) at Month 12 (Table). ACQ-6 and Mini-AQLQ changes from baseline are shown in the Table. TEAEs were reported by 99 patients (48.3%): most commonly asthma (11.7%), COVID-19 (5.9%), acute sinusitis (4.9%), arthralgia (2.0%), headache (2.0%), pneumonia (2.0%), sinusitis (2.0%), and upper respiratory tract infection (2.0%). CONCLUSIONS: Patients who initiated dupilumab in the RAPID registry and completed the first 12 months had significantly reduced severe asthma exacerbation rates and improved asthma control and quality of life. Tolerability was consistent with the known safety profile of dupilumab in adults and adolescents.These data confirm the effectiveness and safety of dupilumab in a real-world clinical setting.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
勤劳的瑀发布了新的文献求助10
刚刚
imfangyu完成签到,获得积分10
1秒前
四夕完成签到 ,获得积分10
1秒前
慕容平安完成签到,获得积分10
2秒前
3秒前
燕燕完成签到,获得积分10
3秒前
chess完成签到,获得积分10
4秒前
领导范儿的应助被aaaq采纳,获得10
4秒前
呆萌保温杯完成签到,获得积分10
5秒前
yangwenjie1212完成签到 ,获得积分10
5秒前
dw完成签到 ,获得积分10
6秒前
重要白亦完成签到 ,获得积分10
6秒前
传奇3的应助被鲤鱼烧鹅采纳,获得10
7秒前
7秒前
FashionBoy的应助被燕燕采纳,获得10
7秒前
大模型的应助被Dtt采纳,获得10
7秒前
是个宝耶完成签到 ,获得积分10
8秒前
香蕉觅云的应助被鼻毛好胜采纳,获得10
10秒前
勤劳的乐安完成签到,获得积分10
10秒前
米奇奇奇完成签到,获得积分10
12秒前
托伐普坦完成签到,获得积分10
12秒前
nn完成签到 ,获得积分10
13秒前
Gorion完成签到,获得积分10
13秒前
科研通AI6.3的应助被张l采纳,获得10
14秒前
今后的应助被谨慎笙采纳,获得30
14秒前
小李要上进完成签到 ,获得积分10
15秒前
Owen的应助被这两天天气咋样采纳,获得10
16秒前
刘宇童完成签到 ,获得积分10
16秒前
wwwww完成签到 ,获得积分10
17秒前
清脆世界完成签到 ,获得积分10
17秒前
桑格利亚完成签到 ,获得积分10
17秒前
18秒前
KK完成签到,获得积分10
18秒前
lakersyoung0完成签到,获得积分10
18秒前
叶云夕完成签到,获得积分10
19秒前
after_17完成签到,获得积分10
20秒前
qiuzhuzhe完成签到,获得积分10
20秒前
须臾完成签到 ,获得积分10
21秒前
曦晨完成签到,获得积分20
21秒前
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194810
求助须知:如何正确求助?哪些是违规求助? 9580544
关于积分的说明 21871741
捐赠科研通 7794414
什么是DOI,文献DOI怎么找? 3437768
关于科研通互助平台的介绍 2561095
邀请新用户注册赠送积分活动 2484480